Cargando…

Atezolizumab and nab-Paclitaxel in Advanced Triple-Negative Breast Cancer: Biomarker Evaluation of the IMpassion130 Study

BACKGROUND: Understanding the impact of the tumor immune microenvironment and BRCA1/2-related DNA repair deficiencies on the clinical activity of immune checkpoint inhibitors may help optimize both patient and treatment selection in metastatic triple-negative breast cancer. In this substudy from the...

Descripción completa

Detalles Bibliográficos
Autores principales:	Emens, Leisha A, Molinero, Luciana, Loi, Sherene, Rugo, Hope S, Schneeweiss, Andreas, Diéras, Véronique, Iwata, Hiroji, Barrios, Carlos H, Nechaeva, Marina, Nguyen-Duc, Anh, Chui, Stephen Y, Husain, Amreen, Winer, Eric P, Adams, Sylvia, Schmid, Peter
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2021
Materias:	Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8328980/ https://www.ncbi.nlm.nih.gov/pubmed/33523233 http://dx.doi.org/10.1093/jnci/djab004

Ejemplares similares

LBA16 IMpassion130: Final OS analysis from the pivotal phase III study of atezolizumab + nab-paclitaxel vs placebo + nab-paclitaxel in previously untreated locally advanced or metastatic triple-negative breast cancer
por: Emens, L.A., et al.
Publicado: (2020)

PD-L1 Immunohistochemistry Assay Comparison in Atezolizumab Plus nab-Paclitaxel–Treated Advanced Triple-Negative Breast Cancer
por: Rugo, Hope S, et al.
Publicado: (2021)

ESMO 2018 presidential symposium—IMpassion130: atezolizumab+nab-paclitaxel in triple-negative breast cancer
por: Schmid, Peter
Publicado: (2018)

Subgroup analysis of Japanese patients in a Phase 3 study of atezolizumab in advanced triple-negative breast cancer (IMpassion130)
por: Iwata, Hiroji, et al.
Publicado: (2019)

Corrigendum to: Subgroup analysis of Japanese patients in a Phase 3 study of atezolizumab in advanced triple-negative breast cancer (IMpassion130)
por: Iwata, Hiroji, et al.
Publicado: (2020)

Quantitative systems pharmacology model predictions for efficacy of atezolizumab and nab-paclitaxel in triple-negative breast cancer
por: Wang, Hanwen, et al.
Publicado: (2021)

Atezolizumab in metastatic triple-negative breast cancer: IMpassion130 and 131 trials - how to explain different results?
por: Franzoi, Maria Alice, et al.
Publicado: (2020)

Carboplatin, nab-paclitaxel plus atezolizumab in IMpower 130 trial: new weapons beyond controversies
por: De Giglio, Andrea, et al.
Publicado: (2019)

Tumor immune microenvironment and genomic evolution in a patient with metastatic triple negative breast cancer and a complete response to atezolizumab
por: Molinero, Luciana, et al.
Publicado: (2019)

Subgroup analysis of Japanese patients in a phase III randomized, controlled study of neoadjuvant atezolizumab or placebo, combined with nab-paclitaxel and anthracycline-based chemotherapy in early triple-negative breast cancer (IMpassion031)
por: Saji, Shigehira, et al.
Publicado: (2022)

Impassable Strictures of the Urethra
por: Roberts, James
Publicado: (1920)

Impasses na América Latina
Publicado: (2005)

The Treatment of Impassable Urethral Stricture
por: Duke, J.
Publicado: (1896)

The Bristol Royal Infirmary Impasse
por: Williams, P. Watson
Publicado: (1907)

The Bristol Royal Infirmary Impasse
Publicado: (1907)

Misdiagnosis and therapeutic impasse in psychiatry
por: Zrelli, M., et al.
Publicado: (2022)

An Impasse at the Royal Victoria Infirmary, Newcastle
Publicado: (1908)

It’s TIME for a biomarker-driven approach to cancer immunotherapy
por: Emens, Leisha A.
Publicado: (2016)

COVID-19:: An impasse between livelihood and health
por: Jayakumar, Karthi
Publicado: (2020)

Cognitive enhancement and authenticity: moving beyond the Impasse
por: Gordon, Emma C.
Publicado: (2022)

El impasse del sujeto : Badiou, la sociología y la modernidad /
por: Olivo Pérez, Miguel Ángel
Publicado: (2017)

Patterns and Predictors of First-Line Taxane Use in Patients with Metastatic Triple-Negative Breast Cancer in US Clinical Practice
por: O’Shaughnessy, Joyce, et al.
Publicado: (2021)

Correction: Quantitative systems pharmacology model predictions for efficacy of atezolizumab and nab-paclitaxel in triple-negative breast cancer
Publicado: (2021)

Combined atezolizumab and nab-paclitaxel in the treatment of triple negative breast cancer: a meta-analysis on their efficacy and safety
por: Sharmni Vishnu, K., et al.
Publicado: (2022)

Impassioned observers reveal the world in a grain of sand
por: Doerr, A
Publicado: (2003)

Surveying the Geneva impasse: Coercive care and human rights
por: Martin, Wayne, et al.
Publicado: (2019)

The balloon impasse sign in percutaneous transvenous mitral valvuloplasty
por: Simard, Trevor, et al.
Publicado: (2020)

Introducing the clinical trials monitor: a new section of the journal for immunotherapy of cancer
por: Emens, Leisha A., et al.
Publicado: (2015)

Atezolizumab With Neoadjuvant Anti–Human Epidermal Growth Factor Receptor 2 Therapy and Chemotherapy in Human Epidermal Growth Factor Receptor 2–Positive Early Breast Cancer: Primary Results of the Randomized Phase III IMpassion050 Trial
por: Huober, Jens, et al.
Publicado: (2022)

Long-term Pooled Safety Analysis of Palbociclib in Combination With Endocrine Therapy for HR+/HER2- Advanced Breast Cancer
por: Diéras, Véronique, et al.
Publicado: (2018)

Long‐Term Pooled Safety Analysis of Palbociclib in Combination with Endocrine Therapy for Hormone Receptor‐Positive/Human Epidermal Growth Factor Receptor 2‐Negative Advanced Breast Cancer: Updated Analysis with up to 5 Years of Follow‐Up
por: Finn, Richard S., et al.
Publicado: (2021)

Effect of palbociclib plus endocrine therapy on time to chemotherapy across subgroups of patients with hormone receptor‒positive/human epidermal growth factor receptor 2‒negative advanced breast cancer: Post hoc analyses from PALOMA-2 and PALOMA-3
por: Rugo, Hope S., et al.
Publicado: (2022)

Tumor Lysis Syndrome After a Single Dose of Atezolizumab with Nab-Paclitaxel: A Case Report and Review of Literature
por: Carrier, Xavier, et al.
Publicado: (2020)

Atezolizumab in combination with carboplatin plus nab‐paclitaxel for managing combined large‐cell neuroendocrine carcinoma: A case report
por: Tsutsumi, Rei, et al.
Publicado: (2022)

Concerning the Operation of John Hunter in Certain Cases of Impassable Stricture
por: Macdougall, J. A.
Publicado: (1879)

IVF in Sri Lanka: A concise history of regulatory impasse
por: Simpson, Bob
Publicado: (2016)

Promoting human rights in mental healthcare: beyond the ‘Geneva impasse’
por: Stavert, Jill, et al.
Publicado: (2023)

Targeting adenosine for cancer immunotherapy
por: Leone, Robert D., et al.
Publicado: (2018)

Understanding conflicting cultural models of outdoor cats to overcome conservation impasse
por: Leong, Kirsten M., et al.
Publicado: (2020)

Editorial: New Perspectives to Unlock the Current Impasse in Treating Anorexia Nervosa
por: Gutierrez, Emilio, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_6bkqcpch38g3bb99bbqet59jgk